Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 581, 263-264 (2020)
doi: https://doi.org/10.1038/d41586-020-01281-0
Updates & Corrections
-
Update 16 July 2020: This article has been updated with additional information about the author’s competing interests.
References
Nature https://doi.org/10.1038/nature.2016.19136 (2016).
Sender, R., Fuchs, S. & Milo, R. PLoS Biol. 14, e1002533 (2016).
Qin, J. et al. Nature 464, 59–65 (2010).
Vieira-Silva, S. et al. Nature 581, 310–315 (2020).
Arumugam, M. et al. Nature 473, 174–180 (2011).
Vieira-Silva, S. et al. Nature Microbiol. 4, 1826–1831 (2019).
Costea, P. I. et al. Nature Microbiol. 3, 8–16 (2018).
Graham, C., Mullen, A. & Whelan, K. Nutr. Rev. 73, 376–385 (2015).
Tang, W. H. W., Bäckhed, F., Landmesser, U. & Hazen, S. L. J. Am. Coll. Cardiol. 73, 2089–2105 (2019).
Baxter, N. T. et al. mBio 10, e02566-18 (2018).
Falony, G. et al. Science 352, 560–564 (2016).
Collins, R. et al. Lancet 388, 2532–2561 (2016).
Oesterle, A., Laufs, U. & Liao, J. K. Circ. Res. 120, 229–243 (2017).
Competing Interests
The author has a financial interest in Xbiotech, a company developing therapeutic human antibodies. The author's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. The author is also an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron and XBiotech. He is a member of scientific advisory boards for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis and XBiotech. He serves on the board of XBiotech. His laboratory has received research funding in the past two years from Novartis.